Open AccessFrequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab
Author(s) -
Kosuke Mizutani,
Toshiki Ito,
Kiyoshi Takahara,
Ryosuke Ando,
Takuma Ishihara,
Takahiro Yasui,
Ryoichi Shiroki,
Hideaki Miyake,
Takuya Koie
Publication year - 2021
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000025402
Subject(s) - medicine , nivolumab , adverse effect , renal cell carcinoma , odds ratio , logistic regression , oncology , cancer , immunotherapy